$90.61
-1.13-1.23%
Last update: Nov 10, 4:00 PM
Inhibrx Biosciences Inc
INBXNASDAQ
Inhibrx Biosciences rose 16.1% from $79.00 to $91.74, ahead of the S&P 500's +10.0%. Its worst day was Oct 28 (−23.4%), and its low came Mar 27 at $58.39.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-2.28 missed the $-2.21 estimate on $0.00 revenue.
+6.0% · S&P 500 0.0%
EPS of $-2.11 beat the $-2.45 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−6.1% · S&P 500 −1.4%
Inhibrx Biosciences shares rose 36.9%, while the S&P 500 rose 1.0%.
+36.9%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 +1.0%
Inhibrx Biosciences closed at its highest level of the year, 79.5% above where the year started.
+10.7% · S&P 500 +1.4%
EPS of $-2.15 missed the $-1.43 estimate on $0.00 revenue.
−6.5% · S&P 500 −1.2%
EPS of $-2.34 missed the $-2.32 estimate on $0.00 revenue.
−8.9% · S&P 500 −0.2%
Inhibrx Biosciences shares rose 16.9%, while the S&P 500 rose 0.3%.
+16.9% · S&P 500 +0.3%
Inhibrx Biosciences shares fell 23.4%, while the S&P 500 rose 0.3%.
−23.4%, the year's worst day · S&P 500 +0.3%
Where it ended: a close of $91.74 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-2.38).
Nothing in the past 12 months.
All INBX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INBX and SPY from Benzinga historical bars. Not investment advice.
